An Original Article published today reported a second-generation monoclonal antibody (mAb) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection.
The recently approved single-dose Beyfortus™ (nirsevimab) was found in a phase 3 clinical study that (0.3%) of infants who received Beyfortus were hospitalized for RSV-associated lower respiratory tract infection compared with 1.5% of those who received standard care.
Read More
